<DOC>
	<DOCNO>NCT00716794</DOCNO>
	<brief_summary>This phase I/II , open-label , dose escalation study HE3235 administer orally patient advanced prostate cancer fail hormone therapy least one taxane base chemotherapy regimen .</brief_summary>
	<brief_title>A Phase I/II Study HE3235 Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Main Patient male least 18 year age , time screening ; Patient metastatic disease ( T , N , M1 ) ; Patient fail least 1 taxane regimen ; Patient symptomatic asymptomatic CRPC chemotherapynaiÌˆve Patient histologically cytologically confirm adenocarcinoma prostate ; Patient progression disease despite adequate hormone therapy , demonstrate one following : PSA level least 2 ng/ml rise least 2 successive occasion , least 1 week apart . Evaluable disease progression modify RECIST ( Response Evaluation Criteria Solid Tumors ) criterion ; Progression metastatic bone disease bone scan &gt; 2 new lesion Patient ECOG ( Eastern Cooperative Oncology Group ) performance status 02 ; Main Patient symptomatic parenchymal brain metastasis active epidural disease require wholebrain irradiation Treated epidural disease allow Patient active infection ; Patient history clinically significant cardiovascular disease ( CHF ) , clinically significant hepatic , respiratory renal abnormality ; Patient clinically significant abnormality laboratory result screen Patient history clinically significant neurological psychiatric condition ; Additional criterion applicable expansion cohort .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>HE3235</keyword>
	<keyword>Apoptone</keyword>
</DOC>